Peter Cancelmo - Investor Relations Gregory Demopulos - Chairman and Chief Executive Officer Michael Jacobsen - Chief Accounting Officer Steven Whitaker - Vice President, Clinical Development Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Operator Peter Cancelmo Now I would like to turn the call over to Dr. Greg Demopulos, Omeros' Chairman and CEO. The question-and-answer period will follow Mike's remarks. For those of you that frequent ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to Commission file number: 001-34475 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washington 91-1663741 ...

Exhibit 99.1 Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – April 1, 2024 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced ...

I remember for those of you who have or can obtain access to ASH either in person or remotely the Phase 2 clinical update on OMS906 program will be presented by Dr. Jens Panse on Sunday, December 10, at 5:00 PM Pacific Time. The presentation will provide a good sense of where our MASP-3 alternative pathway inhibitor program stands relative to other alternative pathway inhibitor programs. As underscored today, we believe that we control the premier target in MASP-3 in the premier drug and OMS906 in the alter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or Washington 91-1663741 (State or other jurisdiction of incorporation or organization) 201 Elliott Avenue West Seattle, Washington 98119 (Address of principal executive offices) (Zip Code) Identification Number) (206) 676-5000 (Registrant's telephone number, i ...

Glomerular deposition of lectin pathway pattern recognition molecules like MBL is known to be associated with more severe glomerular damage as well as more severe proteinuria and hematuria, all of this meaning more severe IgA nephropathy. Studies also show that the lectin pathway contributes to tubulointerstitial fibrosis and IgA nephropathy. The lectin pathway is the only complement pathway linked to tubulointerstitial damage, which is thought to be the common road to a wide range of end-stage kidney disea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34475 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washington 91-1663741 (State o ...

Omeros Corporation (NASDAQ:OMER) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Nadia Dac - Chief Commercial Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Greg Harrison - Bank of America Elliott Bosco - UBS Brandon Folkes - Cantor Fitzgerald Operator Good afternoon, an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34475 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washington 91-1663741 (State ...

The $408 million now in hand provides Omeros the flexibility simply to pay off any or all of the $95 million of convertible debt that matures this November, while continuing to fund operations and advancing our multiple development programs well into 2025. Detailed clinical data from that study were presented in December at the Annual Meeting of the American Society of Hematology. Based on clinical data to-date, we expect that we will be able to achieve once quarterly dosing with OMS906 either intravenously ...